要約
Most gene-editing companies sell nothing. They spend money developing treatments that may or may not work, funded by investors, and their value rests entirely on what might happen years from now. The two numbers that describe such a company best are how much cash it holds and how fast it is spending it — the second divided into the first gives its runway, the time before it must raise more money or stop.
Gene-editing companies are typically pre-revenue, financing multi-year development through equity issuance and partnerships. Key disclosures are cash and equivalents, quarterly operating expenses, implied runway, and the timing of clinical catalysts. Partnership structures — upfront payments, development and commercial milestones, royalties — transfer risk and capital in exchange for economics. Value is concentrated in binary events: a trial readout, a regulatory decision, a clinical hold.
Where to find the real numbers
This site does not carry financial data, because a figure that is stale by minutes is worse than none. For US-listed companies, quarterly and annual filings on the SEC's EDGAR system state cash, operating expenses and risk factors in the company's own words. ClinicalTrials.gov gives trial status. Regulatory decisions are published by the FDA and EMA. Those are the primary sources; everything else is commentary.
Sources
- U.S. Securities and Exchange Commission
EDGAR company filings search ↗